MetaCap

CryoPort Inc. (CYRX)

NASDAQ: CYRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

19.05-0.50 (-2.56%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CYRX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$964.87M
EPS (TTM)
-$0.90
52-week range
7.61 – 21.78
Day range
18.83 – 19.45
Volume / Avg
814.78K / 843.80K
Beta
—

52-week range

$7.61$21.78

CYRX stock today

Shares of CryoPort (CYRX) finished lower on Nov 20 at $19.05, a drop of 2.56% or $0.50 per share, versus the S&P 500's 3.70% decline. At this level, CYRX sits near the top of its 52-week range of $7.61 to $21.78: 12.5% below the high, set on Nov 11, 2026 and 150.3% above the low. CYRX is up 98.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 117.0%.

CryoPort has posted a net loss over the last twelve months (EPS of -$0.90), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About CryoPort

Company profile

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Jerrell W. Shelton
Headquarters
Brentwood, TN
Employees
684

Financial highlights

Full financials

In fiscal 2025, CryoPort generated $176.2 million in revenue, up 12.4% from fiscal 2024. Net income was $78.3 million, for a net margin of 44.4% versus a median of -59.0% in the prior 5 years. Gross margin was 47.1% (up from 44.4%) and operating margin -20.9%.

CryoPort annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2020
Revenue$176.18M$156.77M$168.66M$237.28M$222.61M
Growth+12.38%-7.05%-28.92%+6.59%+182.87%
Net income$78.30M$-114.76M$-99.59M$-37.33M$-275.53M
EPS (diluted)$1.40$-2.49$-2.21$-0.93$-6.18

Analyst forecast

Forecast

Consensus (9 analysts)

strong_buy

Avg. price target

$22.33+17.22%

  • Strong buy 1
  • Buy 7
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $18.00High $28.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.18 vs $-0.19
Surprise
+5.26%

CYRX news

All CYRX news

CryoPort peers

Health Care sector
CYRX peer companies
CompanyPrice% ChgMarket capCompare
SPTXSeaport Therapeutics Inc.18.05-1.47%$966.23Mvs CYRX
OMEROmeros Corporation13.21-5.71%$983.66Mvs CYRX
MLTXMoonLake Immunotherapeutics Class A11.07+0.36%$942.13Mvs CYRX
SVRASavara Inc.4.26-18.23%$939.86Mvs CYRX
ANROAlto Neuroscience Inc.25.37-4.30%$1.02Bvs CYRX
AKTSAktis Oncology Inc.16.15-1.52%$901.14Mvs CYRX
CTYCity Therapeutics Inc.19.32+5.29%$1.03Bvs CYRX
NKTRNektar Therapeutics30.20-7.19%$1.03Bvs CYRX

Indexes, lists and sector

CryoPort stock FAQ

What is CryoPort's stock price today?

CYRX last traded at $19.05 as of Nov 20, 4:00 PM EST, down 2.56% on the day. Prices are delayed at least 15 minutes.

Does CryoPort pay a dividend?

No. CryoPort does not currently pay a regular cash dividend.

Who is CryoPort's CEO?

Mr. Jerrell W. Shelton is the chief executive officer of CryoPort Inc., which has about 684 employees.

Has CYRX ever split its stock?

Yes. The most recent CYRX stock split was a 1-for-12 split on May 19, 2015, one of 2 splits on record.

What is the CYRX 52-week high?

The 52-week high for CYRX is $21.78 and the 52-week low is $7.61. The stock is currently 12.5% below its high.

Compare CYRX